Table 2 A cross tabulation of receptor status and intrinsic molecular subtype
Molecular subtype (research values) | Total | Receptor status | |||||||
|---|---|---|---|---|---|---|---|---|---|
ER+ | ER− | PR+ | PR− | HER2+ | HER2− | Triple negative | Others | ||
All cases | 91 | 85% (77/91) | 15% (14/91) | 79% (72/91) | 21% (19/91) | 21% (19/91) | 79% (72/91) | 12% (11/91) | 88% (80/91) |
Normal-like | 5% (4/84) | 100% (4/4) | 0% (0/4) | 100% (4/4) | 0% (0/4) | 25% (1/4) | 75% (3/4) | 0% (0/4) | 100% (4/4) |
Luminal A | 65% (55/84) | 100% (55/55) | 0% (0/55) | 95% (52/55) | 5% (3/55) | 15% (8/55) | 85% (47/55) | 0% (0/55) | 100% (55/55) |
Luminal B | 12% (10/84) | 100% (10/10) | 0% (0/10) | 80% (8/10) | 20% (2/10) | 40% (4/10) | 60% (6/10) | 0% (0/10) | 100% (10/10) |
HER2-enriched | 6% (5/84) | 60% (3/5) | 40% (2/5) | 40% (2/5) | 60% (3/5) | 100% (5/5) | 0% (0/5) | 0% (0/5) | 100% (5/5) |
Basal-like | 12% (10/84) | 10% (1/10) | 90% (9/10) | 10% (1/10) | 90% (9/10) | 10% (1/10) | 90% (9/10) | 90% (9/10) | 10% (1/10) |
Not determined | 7 | 57% (4/7) | 43% (3/7) | 71% (5/7) | 29% (2/7) | 0% (0/7) | 100% (7/7) | 29% (2/7) | 71% (5/7) |
